Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients

Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet, in spite of this therapy, patients with vs. patients without diabetes have an adverse disease course. In fact, glucose homoeostasis has influ...

Descripción completa

Detalles Bibliográficos
Autores principales: Marfella, R., Paolisso, P., Sardu, C., Bergamaschi, L., D’Angelo, E.C., Barbieri, M., Rizzo, M.R., Messina, V., Maggi, P., Coppola, N., Pizzi, C., Biffi, M., Viale, P., Galié, N., Paolisso, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241396/
https://www.ncbi.nlm.nih.gov/pubmed/32447102
http://dx.doi.org/10.1016/j.diabet.2020.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241396/
https://www.ncbi.nlm.nih.gov/pubmed/32447102
http://dx.doi.org/10.1016/j.diabet.2020.05.005

Ejemplares similares